A palatinose-based balanced formula improves glucose tolerance, serum free fatty acid levels and body fat composition. 2007

Toshihide Oizumi, and Makoto Daimon, and Yumi Jimbu, and Wataru Kameda, and Nobuko Arawaka, and Hiroshi Yamaguchi, and Hiroshi Ohnuma, and Hajime Sasaki, and Takeo Kato
Department of Neurology, Hematology, Metabolism, Endocrinology and Diabetology, Yamagata University School of Medicine, Japan.

Palatinose is a disaccharide present in honey, which has the characteristics of delayed digestion and absorption. We developed a palatinose-based balanced formula (PBF) and reported its beneficial effects on metabolic syndrome-related parameters in rats. To examine the effects of PBF in humans, we here conducted a crossover study using twenty-three subjects with impaired glucose tolerance. The subjects were divided into two groups: intervention to control (I/C) and control to intervention (C/I) groups. The I/C group consumed PBF (250 kcal) together with foods that were 250 kcal less than their usual breakfast (intervention meal) for the first 12 weeks, followed by their usual breakfast (control meal) for the last 12 weeks. The protocol for the C/I group was opposite in order: the control meal for the first 12 weeks, followed by the intervention meal for the last 12 weeks. In the first 12-week period, the intervention meal decreased 2-hr plasma glucose levels after 75-g oral glucose tolerance test (-15.7 +/- 20.1% change), while the control meal did not (0.8 +/- 31.6% change). The difference between these changes was significant (p = 0.038). The similar results were obtained from the comparison of the changes between the first and the last 12-week periods in the two groups combined (intervention vs control: -11.8 +/- 22.5 vs 11.2 +/- 30.2% change, p = 0.024). PBF also had the beneficial effects on serum free fatty acids levels and visceral fat area. In conclusion, PBF consumption has beneficial effects on metabolic syndrome-related parameters in humans.

UI MeSH Term Description Entries
D007534 Isomaltose A disaccharide consisting of two glucose units in an alpha (1-6) glycosidic linkage.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids
D005260 Female Females
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000273 Adipose Tissue Specialized connective tissue composed of fat cells (ADIPOCYTES). It is the site of stored FATS, usually in the form of TRIGLYCERIDES. In mammals, there are two types of adipose tissue, the WHITE FAT and the BROWN FAT. Their relative distributions vary in different species with most adipose tissue being white. Fatty Tissue,Body Fat,Fat Pad,Fat Pads,Pad, Fat,Pads, Fat,Tissue, Adipose,Tissue, Fatty
D018149 Glucose Intolerance A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION. Impaired Glucose Tolerance,Glucose Intolerances,Glucose Tolerance, Impaired,Glucose Tolerances, Impaired,Impaired Glucose Tolerances,Intolerance, Glucose,Intolerances, Glucose,Tolerance, Impaired Glucose,Tolerances, Impaired Glucose

Related Publications

Toshihide Oizumi, and Makoto Daimon, and Yumi Jimbu, and Wataru Kameda, and Nobuko Arawaka, and Hiroshi Yamaguchi, and Hiroshi Ohnuma, and Hajime Sasaki, and Takeo Kato
April 1979, The Indian journal of medical research,
Toshihide Oizumi, and Makoto Daimon, and Yumi Jimbu, and Wataru Kameda, and Nobuko Arawaka, and Hiroshi Yamaguchi, and Hiroshi Ohnuma, and Hajime Sasaki, and Takeo Kato
April 1990, International journal of obesity,
Toshihide Oizumi, and Makoto Daimon, and Yumi Jimbu, and Wataru Kameda, and Nobuko Arawaka, and Hiroshi Yamaguchi, and Hiroshi Ohnuma, and Hajime Sasaki, and Takeo Kato
October 1986, Diabetes,
Toshihide Oizumi, and Makoto Daimon, and Yumi Jimbu, and Wataru Kameda, and Nobuko Arawaka, and Hiroshi Yamaguchi, and Hiroshi Ohnuma, and Hajime Sasaki, and Takeo Kato
November 2003, Zhonghua nei ke za zhi,
Toshihide Oizumi, and Makoto Daimon, and Yumi Jimbu, and Wataru Kameda, and Nobuko Arawaka, and Hiroshi Yamaguchi, and Hiroshi Ohnuma, and Hajime Sasaki, and Takeo Kato
December 1969, British medical journal,
Toshihide Oizumi, and Makoto Daimon, and Yumi Jimbu, and Wataru Kameda, and Nobuko Arawaka, and Hiroshi Yamaguchi, and Hiroshi Ohnuma, and Hajime Sasaki, and Takeo Kato
June 1974, Life sciences,
Toshihide Oizumi, and Makoto Daimon, and Yumi Jimbu, and Wataru Kameda, and Nobuko Arawaka, and Hiroshi Yamaguchi, and Hiroshi Ohnuma, and Hajime Sasaki, and Takeo Kato
November 1968, Lancet (London, England),
Toshihide Oizumi, and Makoto Daimon, and Yumi Jimbu, and Wataru Kameda, and Nobuko Arawaka, and Hiroshi Yamaguchi, and Hiroshi Ohnuma, and Hajime Sasaki, and Takeo Kato
February 2001, Acta physiologica Scandinavica,
Toshihide Oizumi, and Makoto Daimon, and Yumi Jimbu, and Wataru Kameda, and Nobuko Arawaka, and Hiroshi Yamaguchi, and Hiroshi Ohnuma, and Hajime Sasaki, and Takeo Kato
October 1969, The American journal of digestive diseases,
Toshihide Oizumi, and Makoto Daimon, and Yumi Jimbu, and Wataru Kameda, and Nobuko Arawaka, and Hiroshi Yamaguchi, and Hiroshi Ohnuma, and Hajime Sasaki, and Takeo Kato
December 1974, Rinsho byori. The Japanese journal of clinical pathology,
Copied contents to your clipboard!